Companies in #Schizophrenia
Found 4 companies operating in this sector.
Karuna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for neuropsychiatric disorders, with a focus on muscarinic receptor-targeted treatments.
Lundbeck is a Danish specialty pharmaceutical company focused on central nervous system (CNS) disorders including depression, schizophrenia, Parkinson's disease, and migraine. Vyepti (eptinezumab), its CGRP-targeting migraine therapy, is a key growth asset.
Clinical-stage neuroscience company developing small-molecule therapies for autism spectrum disorder, schizophrenia, and other CNS conditions.
Neumora Therapeutics is a clinical-stage neuroscience company developing precision medicines for brain diseases with high unmet need. Its lead asset NMRA-140 (navacaprant) is a kappa opioid receptor antagonist studied in major depressive disorder, and the company has additional programs in schizophrenia and other CNS indications. Following two Phase 3 failures in mid-2026, Neumora announced a 35% workforce reduction and is discontinuing development of its lead depression asset.